Annovis Bio Files Proxy Statement for June Meeting
Ticker: ANVS · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: ANVS
TL;DR
Annovis Bio proxy filed. Vote on directors & auditors June 17.
AI Summary
Annovis Bio, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 17, 2025. The company, formerly known as QR Pharma, Inc., is seeking shareholder approval for various matters, including the election of directors and the ratification of its independent registered public accounting firm. The filing details executive compensation and other corporate governance items.
Why It Matters
This filing provides shareholders with crucial information regarding corporate governance and proposals to be voted on at the upcoming annual meeting, impacting their investment decisions.
Risk Assessment
Risk Level: medium — Proxy statements can reveal changes in corporate strategy, executive compensation, or governance that may impact stock performance.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former company name
- April 30, 2025 (date) — Filing date
- June 17, 2025 (date) — Annual meeting date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with the proxy statement for Annovis Bio, Inc.'s annual meeting of stockholders, detailing information about the matters to be voted upon.
When is the Annovis Bio, Inc. annual meeting scheduled?
The annual meeting of stockholders for Annovis Bio, Inc. is scheduled for June 17, 2025.
What was Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc.
On what date was this definitive proxy statement filed?
This definitive proxy statement was filed on April 30, 2025.
What is the primary business of Annovis Bio, Inc. according to the filing?
Annovis Bio, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding Annovis Bio, Inc. (ANVS).